Evidence map›Paper›PMID 35138524›Full record

ArticleMolecular biology reports2022

Silencing of TP73-AS1 impairs prostate cancer cell proliferation and induces apoptosis via regulation of TP73.

Ahmet Arslan, Bahadir Batar, Ebru Temiz, Hilmi Tozkir, Ismail Koyuncu, Esra Bozgeyik

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ahmet ArslanDepartment of Medical Genetics, Medical Faculty of Tekirdag Namik Kemal University, Tekirdag, Turkey.
Bahadir BatarDepartment of Medical Biology, Medical Faculty of Tekirdag Namik Kemal University, Tekirdag, Turkey.
Ebru TemizProgram of Medical Promotion and Marketing, Vocational School of Health Services, Harran University, Sanliurfa, Turkey.
Hilmi TozkirDepartment of Medical Genetics, Medical Faculty of Tekirdag Namik Kemal University, Tekirdag, Turkey.
Ismail KoyuncuDepartment of Medical Biochemistry, Faculty of Medicine, Harran University, Sanliurfa, Turkey.
Esra BozgeyikDepartment of Medical Services and Techniques, Vocational School of Health Services, Adiyaman University, Adiyaman, Turkey. ebozgeyik@adiyaman.edu.tr.ORCID http://orcid.org/0000-0002-8726-3182
Tekirdağ Namık Kemal University · TRHarran University · TRAdıyaman University · TR

Funding

Tekirdag Namik Kemal University NKUBAP.02.ONAP.19.205
6 · The paper itself

Abstract

backgroundProstate cancer is a malignant disease that severely affects the health and comfort of the male population. The long non-coding RNA TP73-AS1 has been shown to be involved in the malignant transformation of various human cancers. However, whether TP73-AS1 contributes to prostate cancer progression has not been reported yet. Accordingly, here we aimed to report the role of TP73-AS1 in the development and progression of prostate cancer and determine its relationship with TP73. METHODS AND

resultsTP73-AS1-specific siRNA oligo duplexes were used to silence TP73-AS1 in DU-145 and PC-3 cells. Results indicated that TP73-AS1 was upregulated whereas TP73 was downregulated in prostate cancer cells compared to normal prostate cells and there was a negative correlation between them. Besides, loss of function experiments of TP73-AS1 in prostate cancer cells strongly induced cellular apoptosis, interfered with the cell cycle progression, and modulated related pro- and anti-apoptotic gene expression. Colony formation and migration capacities of TP73-AS1-silenced prostate cancer cells were also found to be dramatically reduced.

conclusionsOur findings provide novel evidence that suggests a chief regulatory role for the TP73-TP73-AS1 axis in prostate cancer development and progression, suggesting that the TP73/TP73-AS1 axis can be a promising diagnostic and therapeutic target for prostate cancer.

Indexed as

MicroRNAsProstatic NeoplasmsRNA, Long NoncodingApoptosisCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMaleTumor Protein p73MicroRNAsRNA, Long NoncodingTP73 protein, humanTumor Protein p73LncRNAProstate cancerTP73TP73-AS1

Identifiers

PMID35138524
OpenAlexW4210942385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.